TopFind

AI Summary

We reviewed 6 live results for bat2206 (ustekinumab) and narrowed them down to the 3 options that look most worth comparing first.

The strongest themes across this short list are Immunology and Dermatology.

Comparison Table

Recommended

BAT2206 (Ustekinumab)

Source: Dr. Reddy’s Laboratories

Description

BAT2206 is a biosimilar candidate for Ustekinumab, targeting autoimmune conditions like plaque psoriasis and psoriatic arthritis.

Best for

plaque psoriasis, psoriatic arthritis and autoimmune disease treatment

View Details

Rating

Stelara (ustekinumab)

Source: Janssen

Description

Stelara is the originator ustekinumab biologic, a human interleukin-12 and -23 antagonist. In Singapore, it is HSA-registered for treating plaque psoriasis in both adults and children, as well as psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is delivered via subcutaneous injection or intravenous infusion.

Best for

pediatric psoriasis patients, Singapore-based healthcare users, established biologic treatment and ulcerative colitis management

View Details

Rating

Pyzchiva (Ustekinumab)

Source: Samsung Bioepis

Description

Pyzchiva is an immunology biosimilar for the treatment of autoimmune disorders such as Crohn’s disease and psoriasis.

Best for

Crohn’s disease, psoriasis treatment and immunology patients

View Details

Rating

AI Recommendation

If you want the most balanced option to start with, I recommend:

"BAT2206 (Ustekinumab) from Dr. Reddy’s Laboratories."

I picked this because This biosimilar represents the latest advancements in autoimmune treatments coming to the Philippine market in 2025.

Share this search

Related Finds